Ocena nowatorskiej technologii wielu analitów
Ocena nowatorskiej technologii wielu analitów opartej na cząsteczkach do wykrywania przeciwciał przeciw fibrylarynie
Systemic sclerosis (SSc) is a heterogeneous autoimmune illness related to a number of anti-nuclear antibodies (ANA), together with these within the classification standards (anti-centromere, anti-topoisomerase I (Scl-70), anti-RNA Pol III). Nonetheless, the presence of much less frequent antibodies comparable to anti-fibrillarin (U3-RNP) that generate a clumpy nucleolar sample by HEp-2 oblique immunofluorescence assay (IFA, ICAP AC-9) are thought of illness particular and are with medical subsets of SSc, due to this fact enjoying a job in analysis and prognosis. A particular and delicate anti-fibrillarin assay can be an vital addition to serological analysis and analysis of SSc. The objective of this examine was to judge a brand new particle-based multi-analyte expertise (PMAT) for the measurement of anti-fibrillarin antibodies.
A complete of 149 affected person samples have been collected together with 47 samples from France (Lyon and Paris, n = 32) and Italy (Careggi Hospital, Florence, n = 15) chosen primarily based on AC-9 HEp-2 IFA staining (> 1:640, clumpy nucleolar sample) and 102 non-SSc controls (inflammatory bowel illness (IBD) n = 20, Sjögren’s syndrome (SjS) n = 20, infectious illness (ID) n = 7, systemic lupus erythematosus (SLE) n = 17, rheumatoid arthritis (RA) n = 17, and wholesome people (HI) n = 21). All samples have been examined on the anti-fibrillarin PMAT assay (analysis use solely, Inova Diagnostics, USA). Moreover, the 47 anti-fibrillarin optimistic samples have been additionally examined on PMAT assays for detecting different autoantibodies in ANA-associated rheumatic illnesses (AARD). Anti-fibrillarin antibody knowledge carried out by fluorescence enzyme immunoassay (FEIA, Thermo Fisher, Germany) was obtainable for 34 samples. The anti-fibrillarin PMAT assay was optimistic in 31/32 (96.9%, France) and 12/15 (80.0%, Italy) of samples preselected primarily based on the AC-9 IIF sample (distinction p = 0.09).
Collectively, the PMAT assay confirmed 91.5% (95% confidence interval (CI): 80.1-96.6%) sensitivity with 100.0% (95% CI: 96.4-100.0%) specificity in non-SSc controls. Robust settlement was discovered between PMAT and FEIA with 100.0% optimistic qualitative settlement (34/34) and quantitative settlement (Spearman’s rho = 0.89, 95% CI: 0.77.9-0.95%, p < 0.0001). Though most anti-fibrillarin optimistic samples have been mono-specific (69.8%), some expressed extra antibodies (particularly Scl-70, centromere, dsDNA, Ro52, Ro60, SS-B, Ribo-P, DFS70, and EJ).
In conclusion, this primary examine on anti-fibrillarin antibodies measured utilizing a novel PMAT assay exhibits promising outcomes the place the brand new PMAT assay had excessive degree of settlement to FEIA for the detection of anti-fibrillarin antibodies. The provision of novel AFA assays comparable to PMAT would possibly facilitate the medical deployment, extra research, standardization efforts, and doubtlessly consideration of AFA for subsequent generations of the classification standards.
Mouse Monoclonal anti-human CLEC-2A |
|||
| hAP-0698A | Angio Proteomie | 50ug | EUR 400 |
Sheep Polyclonal anti-Human CLEC-2D |
|||
| hAP-5776 | Angio Proteomie | 50ug | EUR 400 |
CLEC-1 Protein, Human, Recombinant (hFc Tag) |
|||
| MBS8121103-005mg | MyBiosource | 0.05mg | EUR 340 |
CLEC-1 Protein, Human, Recombinant (hFc Tag) |
|||
| MBS8121103-5x005mg | MyBiosource | 5x0.05mg | EUR 1380 |
Mouse Monoclonal anti-human CLEC-2 (CLEC1B) |
|||
| hAP-0188 | Angio Proteomie | 100ug | EUR 250 |
Sheep Polyclonal anti-Human CLEC-2 (CLEC1B) |
|||
| hAP-5775 | Angio Proteomie | 50ug | EUR 400 |
Mouse Monoclonal anti-human Tetranectin (CLEC-3B) |
|||
| hAP-0639 | Angio Proteomie | 100ug | EUR 250 |
Sheep Polyclonal anti-Human Tetranectin (CLEC-3B) |
|||
| hAP-5777 | Angio Proteomie | 50ug | EUR 400 |
Human CLEC-2 HEK293 Overexpression Lysate |
|||
| MBS8114270-03mg | MyBiosource | 0.3mg | EUR 280 |
Human CLEC-2 HEK293 Overexpression Lysate |
|||
| MBS8114270-5x03mg | MyBiosource | 5x0.3mg | EUR 1205 |
OKRC00302-96W - CLEC-2 ELISA Kit (Human) |
|||
| OKRC00302-96W | Aviva Systems Biology | 96Wells | EUR 525 |
CLEC-2 Protein, Human, Recombinant (His Tag) |
|||
| MBS8120607-01mg | MyBiosource | 0.1mg | EUR 450 |
CLEC-2 Protein, Human, Recombinant (His Tag) |
|||
| MBS8120607-1mg | MyBiosource | 1mg | EUR 2530 |
CLEC-2 Protein, Human, Recombinant (His Tag) |
|||
| MBS8120607-5x1mg | MyBiosource | 5x1mg | EUR 11240 |
Human C-type lectin-like receptor 1(CLEC-1) ELISA Kit |
|||
| YLA4238HU-48T | Shanghai YL Biotech | 48T | Ask for price |
Human C-type lectin-like receptor 1(CLEC-1) ELISA Kit |
|||
| YLA4238HU-96T | Shanghai YL Biotech | 96T | Ask for price |
Human CLEC-2 / CLEC1B Protein, His Tag (MALS verified) |
|||
| CL2-H5247 | ACROBIOSYSTEMS | 100ug | EUR 2749.9 |
|
Description: Human CLEC-2, His Tag (CL2-H5247) is expressed from human 293 cells (HEK293). It contains AA Ser 55 - Pro 229 (Accession # Q9P126-1). |
|||
Human CLEC-2 / CLEC1B Protein, Fc Tag (MALS & SPR verified) |
|||
| CL2-H5254 | ACROBIOSYSTEMS | 100ug | EUR 2493.1 |
|
Description: Human CLEC-2, Fc Tag (CL2-H5254) is expressed from human 293 cells (HEK293). It contains AA Ser 55 - Pro 229 (Accession # Q9P126-1). |
|||
Rabbit anti-Caenorhabditis elegans clec-141 Polyclonal Antibody |
|||
| MBS7146187-INQUIRE | MyBiosource | INQUIRE | Ask for price |
Rabbit anti-Caenorhabditis elegans clec-160 Polyclonal Antibody |
|||
| MBS7155259-INQUIRE | MyBiosource | INQUIRE | Ask for price |
Rabbit anti-Caenorhabditis elegans clec-161 Polyclonal Antibody |
|||
| MBS7158228-INQUIRE | MyBiosource | INQUIRE | Ask for price |
Rabbit anti-Caenorhabditis elegans clec-162 Polyclonal Antibody |
|||
| MBS7159039-INQUIRE | MyBiosource | INQUIRE | Ask for price |
Rabbit anti-Caenorhabditis elegans clec-180 Polyclonal Antibody |
|||
| MBS7190225-INQUIRE | MyBiosource | INQUIRE | Ask for price |
Rabbit anti-Caenorhabditis elegans clec-158 Polyclonal Antibody |
|||
| MBS7192271-INQUIRE | MyBiosource | INQUIRE | Ask for price |
Rabbit anti-Caenorhabditis elegans clec-87 Polyclonal Antibody |
|||
| MBS9015280-INQUIRE | MyBiosource | INQUIRE | Ask for price |
Rabbit anti-Caenorhabditis elegans clec-91 Polyclonal Antibody |
|||
| MBS9005737-INQUIRE | MyBiosource | INQUIRE | Ask for price |
Rabbit anti-Caenorhabditis elegans clec-88 Polyclonal Antibody |
|||
| MBS9001663-INQUIRE | MyBiosource | INQUIRE | Ask for price |
CLEC 4E Polyclonal Antibody |
|||
| MBS9238603-01mL | MyBiosource | 0.1mL | EUR 415 |
CLEC 4E Polyclonal Antibody |
|||
| MBS9238603-5x01mL | MyBiosource | 5x0.1mL | EUR 1841 |
CLEC1B/CLEC-2 Rabbit anti-Mouse Polyclonal (N-Terminus) Antibody |
|||
| MBS2402184-005mL | MyBiosource | 0.05mL | EUR 615 |
CLEC1B/CLEC-2 Rabbit anti-Mouse Polyclonal (N-Terminus) Antibody |
|||
| MBS2402184-5x005mL | MyBiosource | 5x0.05mL | EUR 2605 |
Rat CLEC-1 HEK293 Overexpression Lysate |
|||
| MBS8117466-03mg | MyBiosource | 0.3mg | EUR 280 |
Rat CLEC-1 HEK293 Overexpression Lysate |
|||
| MBS8117466-5x03mg | MyBiosource | 5x0.3mg | EUR 1205 |
Mouse CLEC-1 HEK293 Overexpression Lysate |
|||
| MBS8116525-03mg | MyBiosource | 0.3mg | EUR 280 |
Mouse CLEC-1 HEK293 Overexpression Lysate |
|||
| MBS8116525-5x03mg | MyBiosource | 5x0.3mg | EUR 1205 |
Anti-CLEC-1 Antibody |
|||
| MBS8306312-005mL | MyBiosource | 0.05mL | EUR 210 |
Anti-CLEC-1 Antibody |
|||
| MBS8306312-01mL | MyBiosource | 0.1mL | EUR 255 |
Anti-CLEC-1 Antibody |
|||
| MBS8306312-02mL | MyBiosource | 0.2mL | EUR 335 |
Anti-CLEC-1 Antibody |
|||
| MBS8306312-5x02mL | MyBiosource | 5x0.2mL | EUR 1420 |
Recombinant AICL/CLEC-2B |
|||
| MBS201063-001mg | MyBiosource | 0.01mg | EUR 340 |
Recombinant AICL/CLEC-2B |
|||
| MBS201063-005mg | MyBiosource | 0.05mg | EUR 985 |
Recombinant AICL/CLEC-2B |
|||
| MBS201063-5x005mg | MyBiosource | 5x0.05mg | EUR 4180 |
CLEC 4E Antibody HRP Conjugated |
|||
| MBS9461896-01mL | MyBiosource | 0.1mL | EUR 595 |
CLEC 4E Antibody HRP Conjugated |
|||
| MBS9461896-5x01mL | MyBiosource | 5x0.1mL | EUR 2525 |
CLEC 4E Antibody FITC Conjugated |
|||
| MBS9461897-01mL | MyBiosource | 0.1mL | EUR 595 |
CLEC 4E Antibody FITC Conjugated |
|||
| MBS9461897-5x01mL | MyBiosource | 5x0.1mL | EUR 2525 |
Human C-type lectin-like receptor 2(CLEC-2) Elisa Kit |
|||
| YLA4051HU-48T | Shanghai YL Biotech | 48T | Ask for price |
Human C-type lectin-like receptor 2(CLEC-2) Elisa Kit |
|||
| YLA4051HU-96T | Shanghai YL Biotech | 96T | Ask for price |
CLEC-1 Protein, Rat, Recombinant (hFc Tag) |
|||
| MBS8123378-005mg | MyBiosource | 0.05mg | EUR 340 |
CLEC-1 Protein, Rat, Recombinant (hFc Tag) |
|||
| MBS8123378-5x005mg | MyBiosource | 5x0.05mg | EUR 1380 |
CLEC-1 Protein, Mouse, Recombinant (ECD, hFc Tag) |
|||
| MBS8122674-005mg | MyBiosource | 0.05mg | EUR 340 |
CLEC-1 Protein, Mouse, Recombinant (ECD, hFc Tag) |
|||
| MBS8122674-5x005mg | MyBiosource | 5x0.05mg | EUR 1380 |
CLEC 4E Polyclonal Antibody PE Conjugated |
|||
| MBS9464025-01mL | MyBiosource | 0.1mL | EUR 595 |
CLEC 4E Polyclonal Antibody PE Conjugated |
|||
| MBS9464025-5x01mL | MyBiosource | 5x0.1mL | EUR 2525 |
Recombinant Caenorhabditis Elegans clec-159 Protein (aa 1-207) |
|||
| VAng-Ly3238-1mgEcoli | Creative Biolabs | 1 mg (E. coli) | EUR 4216.8 |
|
Description: Caenorhabditis Elegans C-type lectin domain-containing protein 159 (clec-159), recombination protein. |
|||
Recombinant Caenorhabditis Elegans clec-159 Protein (aa 1-207) |
|||
| VAng-Ly3238-500gEcoli | Creative Biolabs | 500 µg (E. coli) | EUR 3013.2 |
|
Description: Caenorhabditis Elegans C-type lectin domain-containing protein 159 (clec-159), recombination protein. |
|||
Recombinant Caenorhabditis Elegans clec-159 Protein (aa 1-207) |
|||
| VAng-Ly3238-50gEcoli | Creative Biolabs | 50 µg (E. coli) | EUR 2056.8 |
|
Description: Caenorhabditis Elegans C-type lectin domain-containing protein 159 (clec-159), recombination protein. |
|||
Mouse CLEC-2 HEK293 Overexpression Lysate |
|||
| MBS8116524-03mg | MyBiosource | 0.3mg | EUR 280 |
Mouse CLEC-2 HEK293 Overexpression Lysate |
|||
| MBS8116524-5x03mg | MyBiosource | 5x0.3mg | EUR 1205 |
CLEC-2 Protein, Mouse, Recombinant (hFc Tag) |
|||
| MBS8122673-01mg | MyBiosource | 0.1mg | EUR 450 |
CLEC-2 Protein, Mouse, Recombinant (hFc Tag) |
|||
| MBS8122673-5x01mg | MyBiosource | 5x0.1mg | EUR 1885 |
Anti-CLEC-6 Antibody |
|||
| MBS8306316-005mL | MyBiosource | 0.05mL | EUR 210 |
Anti-CLEC-6 Antibody |
|||
| MBS8306316-01mL | MyBiosource | 0.1mL | EUR 255 |
Anti-CLEC-6 Antibody |
|||
| MBS8306316-02mL | MyBiosource | 0.2mL | EUR 335 |
Anti-CLEC-6 Antibody |
|||
| MBS8306316-5x02mL | MyBiosource | 5x0.2mL | EUR 1420 |
Anti-CLEC-16A Antibody |
|||
| MBS8306311-005mL | MyBiosource | 0.05mL | EUR 210 |
Anti-CLEC-16A Antibody |
|||
| MBS8306311-01mL | MyBiosource | 0.1mL | EUR 255 |
Anti-CLEC-16A Antibody |
|||
| MBS8306311-02mL | MyBiosource | 0.2mL | EUR 335 |
Anti-CLEC-16A Antibody |
|||
| MBS8306311-5x02mL | MyBiosource | 5x0.2mL | EUR 1420 |
CLEC2 (C-type Lectin Domain Family 2 Member B, 1810061I13Rik, C-type Lectin-like Receptor 2, CLEC 2, CLEC2, CLEC-2, CLEC2B, PRO1384, QDED721) |
|||
| MBS6507282-100Tests | MyBiosource | 100Tests | EUR 860 |
CLEC2 (C-type Lectin Domain Family 2 Member B, 1810061I13Rik, C-type Lectin-like Receptor 2, CLEC 2, CLEC2, CLEC-2, CLEC2B, PRO1384, QDED721) |
|||
| MBS6507282-5x100Tests | MyBiosource | 5x100Tests | EUR 3720 |
Recombinant Caenorhabditis Elegans clec-161 Protein (aa 21-862) |
|||
| VAng-Ly3239-inquire | Creative Biolabs | inquire | Ask for price |
|
Description: Caenorhabditis Elegans C-type lectin domain-containing protein 161 (clec-161), partial, recombination protein. |
|||
Recombinant Caenorhabditis Elegans clec-162 Protein (aa 18-313) |
|||
| VAng-Ly3240-1mgEcoli | Creative Biolabs | 1 mg (E. coli) | EUR 4893.6 |
|
Description: Caenorhabditis Elegans C-type lectin domain-containing protein 162 (clec-162), recombination protein. |
|||
Recombinant Caenorhabditis Elegans clec-162 Protein (aa 18-313) |
|||
| VAng-Ly3240-500gEcoli | Creative Biolabs | 500 µg (E. coli) | EUR 3474 |
|
Description: Caenorhabditis Elegans C-type lectin domain-containing protein 162 (clec-162), recombination protein. |
|||
Recombinant Caenorhabditis Elegans clec-162 Protein (aa 18-313) |
|||
| VAng-Ly3240-50gEcoli | Creative Biolabs | 50 µg (E. coli) | EUR 2370 |
|
Description: Caenorhabditis Elegans C-type lectin domain-containing protein 162 (clec-162), recombination protein. |
|||
Recombinant Caenorhabditis Elegans clec-91 Protein (aa 22-225) |
|||
| VAng-Ly3241-1mgEcoli | Creative Biolabs | 1 mg (E. coli) | EUR 4200 |
|
Description: Caenorhabditis Elegans C-type lectin domain-containing protein 91 (clec-91), recombination protein. |
|||
Recombinant Caenorhabditis Elegans clec-91 Protein (aa 22-225) |
|||
| VAng-Ly3241-500gEcoli | Creative Biolabs | 500 µg (E. coli) | EUR 2997.6 |
|
Description: Caenorhabditis Elegans C-type lectin domain-containing protein 91 (clec-91), recombination protein. |
|||
Recombinant Caenorhabditis Elegans clec-91 Protein (aa 22-225) |
|||
| VAng-Ly3241-50gEcoli | Creative Biolabs | 50 µg (E. coli) | EUR 2040 |
|
Description: Caenorhabditis Elegans C-type lectin domain-containing protein 91 (clec-91), recombination protein. |
|||
Mouse anti Human CLEC4A/CLECSF6/DCIR Monoclonal Antibody |
|||
| MBS2543611-006mL | MyBiosource | 0.06mL | EUR 250 |
Mouse anti Human CLEC4A/CLECSF6/DCIR Monoclonal Antibody |
|||
| MBS2543611-012mL | MyBiosource | 0.12mL | EUR 370 |
Mouse anti Human CLEC4A/CLECSF6/DCIR Monoclonal Antibody |
|||
| MBS2543611-02mL | MyBiosource | 0.2mL | EUR 550 |
Mouse anti Human CLEC4A/CLECSF6/DCIR Monoclonal Antibody |
|||
| MBS2543613-006mL | MyBiosource | 0.06mL | EUR 250 |
Mouse anti Human CLEC4A/CLECSF6/DCIR Monoclonal Antibody |
|||
| MBS2543613-012mL | MyBiosource | 0.12mL | EUR 370 |
Mouse anti Human CLEC4A/CLECSF6/DCIR Monoclonal Antibody |
|||
| MBS2543613-02mL | MyBiosource | 0.2mL | EUR 550 |
Rabbit anti Human CLEC1B Monoclonal Antibody |
|||
| MBS2544129-006mL | MyBiosource | 0.06mL | EUR 250 |
Rabbit anti Human CLEC1B Monoclonal Antibody |
|||
| MBS2544129-012mL | MyBiosource | 0.12mL | EUR 370 |
Rabbit anti Human CLEC1B Monoclonal Antibody |
|||
| MBS2544129-02mL | MyBiosource | 0.2mL | EUR 550 |
Rabbit anti Human CLEC4A Monoclonal Antibody |
|||
| MBS2544240-006mL | MyBiosource | 0.06mL | EUR 250 |
Rabbit anti Human CLEC4A Monoclonal Antibody |
|||
| MBS2544240-012mL | MyBiosource | 0.12mL | EUR 370 |
Rabbit anti Human CLEC4A Monoclonal Antibody |
|||
| MBS2544240-02mL | MyBiosource | 0.2mL | EUR 550 |
Porównywalne endemiczne przeciwciała specyficzne dla nukleoproteiny koronawirusa u pacjentów z łagodnym i ciężkim Covid-19
The severity of illness of Covid-19 is very variable, starting from asymptomatic to essential respiratory illness and demise. Potential cross-reactive immune responses between SARS-CoV-2 and endemic coronavirus (eCoV) might hypothetically contribute to this variability. We herein studied if eCoV Nucleoprotein (N)-specific antibodies within the sera of sufferers with delicate or extreme Covid-19 are related to Covid-19 severity.
There have been comparable ranges of eCoV N-specific antibodies early and throughout the first month of an infection in Covid-19 sufferers with delicate and extreme signs, and wholesome SARS-COV-2-negative topics. These outcomes warrant additional research to analyze the potential position of eCoV-specific antibodies in immunity to SARS-CoV-2 an infection. This text is protected by copyright. All rights reserved.
TOP-Plus to wszechstronna platforma biosensoryczna do monitorowania trwałości przeciwciał SARS-CoV-2
Background: Low preliminary SARS-CoV-2 antibody titers dropping to undetectable ranges inside months after an infection have raised considerations over long run immunity. Each the antibody ranges and avidity of the antibody-antigen interplay ought to be examined to perceive the standard of the antibody response.
Strategies: A testing-on-a-probe “plus” panel (TOP-Plus) was developed, which included a newly developed avidity assay constructed into the beforehand described SARS-CoV-2 TOP assays that measured complete antibody (TAb), surrogate neutralizing antibody (SNAb), IgM and IgG on a flexible biosensor platform. TAb and SNAb ranges have been in contrast with avidity in beforehand contaminated people at 1.three and 6.2 months post-infection in paired samples from 80 COVID-19 sufferers. Sera from SARS-CoV-2 vaccinated people have been additionally evaluated for antibody avidity.
Outcomes: The newly designed avidity assay on this TOP panel correlated nicely with a reference Bio-Layer Interferometry avidity assay (r=0.88). The imprecision of the TOP avidity assay was lower than 10%. Though TAb and neutralization exercise (by SNAb) decreased between 1.three and 6.2 months post-infection, the antibody avidity elevated considerably (P < 0.0001). Antibody avidity in 10 SARS-CoV-2 vaccinated people (median 28 days post-vaccination) was corresponding to the measured antibody avidity in contaminated people (median 26 days post-infection).
Conclusion: This extremely exact and versatile TOP-Plus panel with the power to measure SARS-CoV-2 TAb, SNAb, IgG and IgM antibody ranges and avidity of particular person sera on one sensor can change into a helpful asset in monitoring not solely SARS-CoV-2-infected sufferers, but in addition the standing of people’ COVID-19 vaccination response.
Brak dowodów na zakażenie makrofagami pochodzącymi z ludzkich monocytów i nasilenie zakażenia SARS-CoV-2 za pośrednictwem przeciwciał
Vaccines are important to manage the unfold of extreme acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and to guard the susceptible inhabitants. Nonetheless, one security concern of vaccination is the doable growth of antibody-dependent enhancement (ADE) of SARS-CoV-2 an infection. The potential an infection of Fc receptor bearing cells comparable to macrophages, would assist continued virus replication and inflammatory responses, and thereby doubtlessly worsen the medical final result of COVID-19.
Right here we show that SARS-CoV-2 and SARS-CoV neither infect human monocyte-derived macrophages (hMDM) nor induce inflammatory cytokines in these cells, in sharp distinction to Center East respiratory syndrome (MERS) coronavirus and the frequent chilly human coronavirus 229E. Moreover, serum from convalescent COVID-19 sufferers neither induced enhancement of SARS-CoV-2 an infection nor innate immune response in hMDM. Though, hMDM expressed angiotensin-converting enzyme 2, no or very low ranges of transmembrane protease serine 2 have been discovered. These outcomes assist the view that ADE is probably not concerned within the immunopathological processes related to COVID-19, nonetheless, extra research are essential to know the potential contribution of antibodies-virus complexes with different cells expressing FcR receptors.
